Modulation of FGF receptor signaling as an intervention and potential therapy for myelin breakdown in Alzheimer's disease

Medical Hypotheses

Volumn 80, Issue 4, 2013, Pages 341-344

  Li, Jia Su ^a   Yao, Zhong Xiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CELL DIFFERENTIATION; COGNITIVE DEFECT; GENE TRANSFER; HIPPOCAMPUS; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; WHITE MATTER;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; MICE; MYELIN SHEATH; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

MUS;

EID: 84875391849     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.12.008     Document Type: Article

References (49)

1. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
2. Nelson P.T., Alafuzoff I., Bigio E.H., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012, 71:362-381.
3. Marcello E., Epis R., Saraceno C., Di Luca M. Synaptic dysfunction in Alzheimer's disease. Adv Exp Med Biol 2012, 970:573-601.
4. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
5. Roberson E.D., Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314:781-784.
6. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004, 25:5-18.
7. Bartzokis G., Lu P.H., Mintz J. Quantifying age-related myelin breakdown with MRI: novel therapeutic targets for preventing cognitive decline and Alzheimer's disease. J Alzheimers Dis 2004, 6:S53-S59.
8. Braak H., Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004, 25:19-23.
9. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 2011, 32:1341-1371.
10. Whitman G.T., Cotman C.W. Oligodendrocyte degeneration in AD. Neurobiol Aging 2004, 25:33-36.
11. Sjobeck M., Englund E. Glial levels determine severity of white matter disease in Alzheimer's disease: a neuropathological study of glial changes. Neuropathol Appl Neurobiol 2003, 29:159-169.
12. Braak H., Del Tredici K., Schultz C., Braak E. Vulnerability of select neuronal types to Alzheimer's disease. Ann NY Acad Sci 2000, 924:53-61.
13. Skaper S.D., Evans N.A., Rosin C., Facci L., Richardson J.C. Oligodendrocytes are a novel source of amyloid peptide generation. Neurochem Res 2009, 34:2243-2250.
14. Stokin G.B., Lillo C., Falzone T.L., et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
15. Desai M.K., Sudol K.L., Janelsins M.C., Mastrangelo M.A., Frazer M.E., Bowers W.J. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009, 57:54-65.
16. Desai M.K., Mastrangelo M.A., Ryan D.A., Sudol K.L., Narrow W.C., Bowers W.J. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol 2010, 177:1422-1435.
17. Noble M. The possible role of myelin destruction as a precipitating event in Alzheimer's disease. Neurobiol Aging 2004, 25:25-31.
18. Ford-Perriss M., Abud H., Murphy M. Fibroblast growth factors in the developing central nervous system. Clin Exp Pharmacol P 2001, 28:493-503.
19. Bottcher R.T., Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 2005, 26:63-77.
20. Dono R. Fibroblast growth factors as regulators of central nervous system development and function. Am J Physiol-Reg I 2003, 284:R867-R881.
21. Mason I. Initiation to end point: the multiple roles of fibroblast growth factors in neural development. Nat Rev Neurosci 2007, 8:583-596.
22. Fortin D., Rom E., Sun H.J., Yayon A., Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005, 25:7470-7479.
23. Gibney S.M., McDermott K.W. Differentiation of oligodendrocytes in neurospheres derived from embryonic rat brain using growth and differentiation factors. J Neurosci Res 2007, 85:1912-1920.
24. Furusho M., Kaga Y., Ishii A., Hebert J.M., Bansal R. Fibroblast growth factor signaling is required for the generation of oligodendrocyte progenitors from the embryonic forebrain. J Neurosci 2011, 31:5055-5066.
25. Bansal R., Magge S., Winkler S. Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J Neurosci Res 2003, 74:486-493.
26. Bansal R., Lakhina V., Remedios R., Tole S. Expression of FGF receptors 1, 2, 3 in the embryonic and postnatal mouse brain compared with Pdgfra, Olig2 and Plp/dm20: implications for oligodendrocyte development. Dev Neurosci-Basel 2003, 25:83-95.
27. Kiyota T., Ingraham K.L., Jacobsen M.T., Xiong H.G., Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. P Natl Acad Sci USA 2011, 108:E1339-E1348.
28. Stevens H.E., Jiang G.Y., Schwartz M.L., Vaccarino F.M. Learning and memory depend on fibroblast growth factor receptor 2 functioning in hippocampus. Biol Psychiat 2012, 71:1090-1098.
29. Furusho M., Dupree J.L., Nave K.A., Bansal R. Fibroblast growth factor receptor signaling in oligodendrocytes regulates myelin sheath thickness. J Neurosci 2012, 32:6631-6641.
30. Guardiola-Diaz H.M., Ishii A., Bansal R. Erk1/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiation. Glia 2012, 60:476-486.
31. Narayanan S.P., Flores A.I., Wang F., Macklin W.B. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 2009, 29:6860-6870.
32. Flores A.I., Narayanan S.P., Morse E.N., et al. Constitutively active Akt induces enhanced myelination in the CNS. J Neurosci 2008, 28:7174-7183.
33. Jin K., Sun Y., Xie L., et al. Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell 2003, 2:175-183.
34. Svennerholm L., Gottfries C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 1994, 62:1039-1047.
35. Ziegler D.A., Piguet O., Salat D.H., Prince K., Connally E., Corkin S. Cognition in healthy aging is related to regional white matter integrity, but not cortical thickness. Neurobiol Aging 2010, 31:1912-1926.
36. Lu P.H., Lee G.J., Raven E.P., et al. Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample. J Clin Exp Neuropsychol 2011, 33:1059-1068.
37. Clemente D., Ortega M.C., Arenzana F.J., de Castro F. FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. J Neurosci 2011, 31:14899-14909.
38. Cummings B.J., Su J.H., Cotman C.W. Neuritic involvement within bFGf immunopositive plaques of Alzheimer's disease. Exp Neurol 1993, 124:315-325.
39. Wang S.J., Furusho M., D'Sa C., et al. Inactivation of fibroblast growth factor receptor signaling in myelinating glial cells results in significant loss of adult spiral ganglion neurons accompanied by age-related hearing impairment. J Neurosci Res 2009, 87:3428-3437.
40. Gibson N.J., Tolbert L.P., Oland L.A. Activation of glial FGFRs is essential in glial migration, proliferation, and survival and in glia-neuron signaling during olfactory system development. PLoS One 2012, 7:e33828.
41. Zhao M., Li D., Shimazu K., Zhou Y.X., Lu B., Deng C.X. Fibroblast growth factor receptor-1 is required for long-term potentiation, memory consolidation, and neurogenesis. Biol Psychiat 2007, 62:381-390.
42. Goddard D.R., Berry M., Kirvell S.L., Butt A.M. Fibroblast growth factor-2 inhibits myelin production by oligodendrocytes in vivo. Mol Cell Neurosci 2001, 18:557-569.
43. Cantara S., Ziche M., Donnini S. Opposite effects of beta amyloid on endothelial cell survival: role of fibroblast growth factor-2 (FGF-2). Pharmacol Rep 2005, 57:138-143.
44. Armstrong R.C., Le T.Q., Frost E.E., Borke R.C., Vana A.C. Absence of fibroblast growth factor 2 promotes oligodendroglial repopulation of demyelinated white matter. J Neurosci 2002, 22:8574-8585.
45. Baron W., Metz B., Bansal R., Hoekstra D., de Vries H. PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways. Mol Cell Neurosci 2000, 15:314-329.
46. Gavine P.R., Mooney L., Kilgour E., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012, 72:2045-2056.
47. Lamont F.R., Tomlinson D.C., Cooper P.A., Shnyder S.D., Chester J.D., Knowles M.A. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011, 104:75-82.
48. Brooks A.N., Kilgour E., Smith P.D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012, 18:1855-1862.
49. Dey J.H., Bianchi F., Voshol J., Bonenfant D., Oakeley E.J., Hynes N.E. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010, 70:4151-4162.